Oragenics completes acquisition of Odyssey Health including neuro drug, tech pipelines

Oragenics Inc. has announced the completion of its acquisition of assets related to Odyssey Health Inc., including its proprietary neurological drug therapies and technologies.

According to a joint release, chief among Odyssey’s assets included in the transaction first announced in early October is ONP-002, an intranasal formulation under development to treat moderate to severe concussion in the acute through subacute phases. The novel therapeutic demonstrated safety and tolerability in a phase 1 clinical trial that included healthy human subjects, according to the release. Oragenics is planning further testing in phase 2 studies to assess safety and efficacy.

Oragenics will also acquire the rights to ONP-001, Odyssey’s first-in-class neurosteroid in development for Niemann Pick Type-C Disease, as well as the proprietary powder formulation and its intranasal delivery device, the company said in the release.

“We are delighted to complete this pivotal transaction following a favorable vote of shareholders at both companies,” Oragenics CEO Kim Murphy said in the release. “We expect that Odyssey’s neurological pipeline will significantly expand our market opportunity and believe its technology complements our expertise in intranasal drug delivery.”

Further terms of the acquisition stipulate that the Odyssey management and development team that spearheaded clinical design and implementation for ONP-002 will continue to do so with Oragenics.